

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/153195 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/050220

(22) International Filing Date:

13 January 2022 (13.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/136,938 13 January 2021 (13.01.2021) US

(71) Applicants: **MEMORIAL SLOAN KETTERING CANCER CENTER** [US/US]; 1275 York Avenue, New York, New York 10065 (US). **TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE** [US/US]; 413 East 69th Street, Box 300, New York, New York 10021 (US).

(72) Inventors: **POIRIER, John T.**; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US). **RUDIN, Charles**; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US). **LEWIS, Jason**; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US). **KHAN, Abdul**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **ANDREW, David**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **CHEN, Xinlei**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **LORENZ, Ivo**; c/o Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street, Box 300, New York, New York 10021 (US). **MATSUNAGA, Hironori**; c/o DAIICHI SANKYO COMPANY, LIMITED, 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-DLL3 ANTIBODY-DRUG CONJUGATE

(57) Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.

WO 2022/153195 A1